







Cite this: *CrystEngComm*, 2025, 27, 1707

Structural analysis, *in vitro* anti-tubercular activities, and *in silico* ADMET evaluation of ethyl 7-methoxy-3-(4-substituted benzoyl)indolizine-1-carboxylates†

Rahul D. Nagdeve, ^a Jyoti Swarup Thakur, ^a Sandeep Chandrashekhara, ^b Pradip Kumar Mondal, ^c Pran Kishore Deb, ^d Maurizio Polentarutti, ^c Keshab M. Bairagi, ^{ae} Gourav Rakshit,^d Osama I. Alwassil, ^f Melendhran Pillay, ^g Katharigatta N. Venugopala ^{*hi} and Susanta K. Nayak ^{*a}

Within the context of crucial exploration for innovative tuberculosis drugs, especially to counteract emerging drug resistance, we present a newly developed series of ethyl 3-(4-substituted benzoyl)-7-methoxyindolizine-1-carboxylate analogues with various substituents (**5a–p**) to analyze their anti-tubercular efficacy. The synthesized indolizine derivatives were characterized by several spectroscopic methods such as FT-IR, ¹H-NMR, and ¹³C-NMR. The structural aspects of these derivatives (**5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**) were elucidated using single-crystal X-ray diffraction. Hirshfeld surface analysis and 2D fingerprint plots aided in investigating intermolecular hydrogen bonding and non-covalent interactions, and their impact on crystal packing. Moreover, computational analyses such as MEP, and energy framework calculations have identified the compound's interaction sites and inter-molecular interaction energies. FMO analysis was carried out to determine the global reactivity parameters of the synthesized compounds. NCI and QTAIM studies were conducted to evaluate the nature as well as qualitative and quantitative descriptions of intra and inter-molecular hydrogen bonding interactions present in these molecules and their crystal packing. The *in vitro* whole-cell anti-tubercular activity of the indolizine derivatives (**5a–p**) was evaluated against *Mycobacterium tuberculosis* H37Rv (susceptible), multidrug-resistant, and extensively drug-resistant strains (ATCC 27294 – American type cell culture). It is worth mentioning that some of these molecules (**5a–5h**, **5l**, **5n**, and **5p**) exhibited potent activity against H37Rv and MDR-MTB strains, with minimum inhibitory concentrations ranging from 4–32 µg mL⁻¹. In the case of the XDR-MTB strain, only compounds **5d**, **5e**, **5f**, **5h**, **5l**, and **5n**, showed moderate to good activities with MIC values ranging from 16–128 µg mL⁻¹. Additionally, ADMET (*in silico*) studies of the potent compounds emphasized their drug-likeness, reinforcing their potential as promising compounds for further development as anti-TB agents.

Received 5th October 2024,
Accepted 10th December 2024

DOI: 10.1039/d4ce01018c

rsc.li/crystengcomm

1. Introduction

Tuberculosis (TB) is a highly contagious disease and a significant cause of illness and death, especially among low

socioeconomic groups and marginalized sections of the community. This infectious disease is primarily caused by *Mycobacterium tuberculosis* (MTB), with a predominant impact on the lungs (pulmonary); however, it can disseminate to

^a Department of Chemistry, Visvesvaraya National Institute of Technology (VNIT), Nagpur 440010, Maharashtra, India. E-mail: sknayak@chm.vnit.ac.in

^b Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER-R) Raebareilly, Lucknow, (UP)-226002, India

^c Elettra-Sincrotrone Trieste, S.C.p.A., S. S. 14, Km 163.5 in Area Science Park, Basovizza 34149, Italy

^d Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology (BIT), Mesra, Ranchi 835215, Jharkhand, India

^e Post Graduate Teaching Department of Chemistry, Gondwana University, Gadchiroli, Maharashtra 442605, India

^f Department of Pharmaceutical Sciences, King Saud bin Abdulaziz University for

Health Sciences, Riyadh 11481, Kingdom of Saudi Arabia

^g Department of Microbiology, National Health Laboratory Services, KZN Academic Complex, Inkosi Albert Luthuli Central Hospital, Durban 4001, South Africa

^h Department of Biotechnology and Food Science, Faculty of Applied Sciences, Durban University of Technology, Durban 4001, South Africa

ⁱ Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Kingdom of Saudi Arabia.

E-mail: kvenugopala@kfu.edu.sa

† Electronic supplementary information (ESI) available. CCDC 2380090–2380096. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d4ce01018c>

other organs in the body (extrapulmonary).¹ TB continues to be a major threat to the human population. According to the World Health Organization (WHO), TB is the 13th leading cause of mortality and the second most common infectious disease-related cause of death, after COVID-19.² In 2022, TB resulted in nearly 1.4 million deaths, including 208 000 deaths among HIV/AIDS-positive patients.³ HIV-positive patients are 19 times more likely to develop tuberculosis than HIV-negative individuals. The present threat of TB to global public health is a consequence of the rising number of cases.⁴

Several factors have contributed to the ongoing global health threat of TB, including drug resistance such as multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), and totally drug-resistant tuberculosis (TDR-TB) as well as co-morbidities with acquired immunodeficiency syndrome (AIDS) and the risk factors associated with developing diabetes mellitus in TB patients.⁵ The US Food and Drug Administration (US-FDA) has approved a few medications to advance TB care. When combined with first- or second-line anti-TB drugs, bedaquiline (approved in late 2012 under the FDA's accelerated review program) was found to have strong anti-TB effects and promising activity against MDR and XDR-TB, resulting in reduced treatment duration.^{6,7} However, nausea, elongation of the QT interval, and drug interactions with cytochrome P3A4 inducers and inhibitors have been reported as side effects of bedaquiline.^{8,9} In the latter part of 2013, the European Medicines Agency approved delamanid as the second anti-TB drug.¹⁰ However, there have been recent cases where strains of MTB have acquired resistance to both bedaquiline and delamanid due to prolonged treatment. Pretomanid, the most recent drug candidate from the TB therapeutic pathway, was approved by the FDA in 2019 for the treatment of MDR and XDR TB.¹¹ Despite the availability of drugs, which are often cytotoxic and have reduced efficacy due to the evolution of resistant bacterial strains, there has not been significant progress in anti-TB drug discovery. A recent push for the development of new therapeutic agents to combat MDR, XDR, and TDR-TB has led to the identification of several promising anti-TB candidates.^{12,13} Among these, TBA-7371 (an azaindole) and Q203, or telacebec (an imidazopyridine amide), are particularly promising therapeutic candidates for the prospective treatment of MDR and XDR TB (Fig. S1†).^{9,14}

Nevertheless, there is a growing demand for the development of new drug targets specific to mycobacteria that exhibit efficacy similar to existing anti-TB treatments. One promising approach in combating multidrug-resistant TB (MDR-TB) is the investigation of multi-targeting drugs, which involve a single molecule binding to multiple biological targets.¹⁵ This approach, known as polypharmacology, has shown promising results in improving effectiveness, synergistic effects, and adverse event profiles, while also reducing drug–drug interactions and the risk of resistance development. For example, SQ109, a


therapeutic candidate in the TB drug pipeline, is a known MmpL3 inhibitor with good activity against MTB enzymes MenA and MenG.¹⁶ Additionally, numerous natural products have recently been identified as effective molecules against clinical MDR strains of MTB.¹⁷

Consequently, designing new chemical entities with various mechanisms of action plays a crucial role in treating H37Rv (susceptible), MDR, XDR, and TDR-TB infections.^{8,9} Considering the urgent need to combat emerging drug resistance, there is a strong necessity for novel drug development in tuberculosis treatment. This study continues our research on the design and synthesis of nitrogen-containing heterocyclic compounds, specifically “indolizine”, as anti-TB agents. In synthetic chemistry,^{18–22} indolizines have garnered significant interest due to their importance in various medicinal applications, including treatment for tuberculosis,^{23–27} antioxidant²⁸ properties, anticancer,²⁹ antimicrobial,^{30,31} anti-inflammatory,^{32–35} and larvicidal activity,^{36,37} and as NmeNANAS³⁸ inhibitors. The above evidence propelled us to design, characterize, and evaluate the structure–activity relationship (SAR) by examining the influence of different R₁ and R₂ substitutions on the indolizine scaffold for their anti-tubercular potential against three MTB strains: H37Rv, rifampicin/isoniazid-resistant (MDR), and XDR (Scheme 1).

2. Experimental section

2.1 General chemical synthesis and characterization

All the chemicals for synthesizing the title compounds (**5a–p**) were purchased from Sigma-Aldrich, and/or Tokyo Chemical Industry (TCI) Company, Ltd. The solvents required for synthesis and crystallization were acquired from Thermo Fisher Scientific Company. The compounds were purified by column chromatography using Merck silica gel. Reaction progress was monitored by thin-layer chromatography (TLC) on 0.25 mm Merck 60 F254 silica gel plates, using a petroleum ether and ethyl acetate solvent system. UV light (254 nm and 365 nm) was used for product visualization, and the product was extracted by evaporating the solvent with a Heidolph rotary evaporator. The Bio-Technique vacuum pump and oven were used to dry the compounds. A DBK programmable melting point apparatus was used to determine the melting point of the synthesized compounds



Scheme 1 The synthetic scheme involving the development of ethyl 3-(4-substituted benzoyl)-7-methoxyindolizine-1-carboxylate (**5a–p**); (a) dry acetone, RT, 24 h. (b) K₂CO₃, DMF, RT, 30 min.

(5a–p). The Fourier transform infrared spectra (FT-IR) for indolizine derivatives were recorded on the IR affinity-1 spectrophotometer (Shimadzu) using the KBr diffuse reflectance system (DRS). In addition, NMR (^1H and ^{13}C) spectra were collected on Bruker ADVANCE III 400 MHz instruments in DMSO-d_6 as a solvent with TMS set as an internal standard. The chemical shift (δ) values were expressed in ppm relative to TMS, while the coupling constant (J) values were determined in units of hertz (Hz). The splitting pattern is abbreviated as s, singlet, d, doublet, t, triplet, m, multiplet.

2.2 General synthetic procedure for the preparation of intermediates 4-methoxy-1-(2-(4-substituted phenyl)-2-oxoethyl)pyridin-1-ium bromide (3a–d)

To a stirred solution of 4-methoxy pyridine (0.0107 mol) in 25 mL of dry acetone, 4-substituted phenacyl bromide (0.0107 mol) was added in a 100 mL round-bottom (RB) flask and the reaction mixture was stirred at room temperature for 24 h. The completion of the reaction mixture was monitored using TLC. The solid formed was filtered and dried under vacuum to obtain the intermediate product 4-methoxy-1-(2-(4-substituted phenyl)-2-oxoethyl)pyridin-1-ium bromide (3a–d), with a yield of 96–99%.

2.3 General procedure for the preparation of ethyl 3-(4-substituted benzoyl)-7-methoxyindolizine-1-carboxylates (5a–p)

To a stirred solution of intermediate 4-methoxy-1-(2-(4-substituted phenyl)-2-oxoethyl)pyridin-1-ium bromide (3a–d) (0.0024 mol) and anhydrous K_2CO_3 (0.0048 mol) in 10 mL of dry DMF solvent in a 50 mL RB flask, substituted alkyne carboxylate (0.0024 mol) was added and stirred for 30 min at room temperature. The completion of the reaction mixture was monitored using TLC. After the reaction was completed,

the reaction mixture was poured into cold water and extracted with ethyl acetate (50 mL), and then evaporated under reduced pressure with the help of a Heidolph rotary evaporator. Further, the obtained solid was purified through column chromatography using 60–120 mesh silica gel with petroleum ether (60–80), and ethyl acetate was used as an eluent solvent in the ratio (7:3) to obtain the pure ethyl 3-(4-substituted benzoyl)-7-methoxyindolizine-1-carboxylate (5a–p). The product yield is in the range of 60–82% (Table 1), and the plausible mechanism route for the synthesized compounds (5a–p) is mentioned in Fig. S2†. The physicochemical constants of ethyl 3-(4-substituted benzoyl)-7-methoxyindolizine-1-carboxylate derivatives are tabulated in Table 1, and the characterization details are reported in the ESI† (Fig. S3–S35).

2.4 Methods for the growth of single crystals

A minimum 5 mg amount of compound (purified by column chromatography) was taken in a 5 mL glass vial and dissolved in a small amount (1–2 mL) of ethanol solvent to obtain a single crystal. After the proper dissolution of compounds (5a–p), it was covered with parafilm, and 3 to 4 small holes were made on the top. The glass vial was then kept for slow evaporation at low temperatures under dust-free and vibration-free conditions to obtain single crystals (Fig. S36†), and a Nikon (H600L) polarized optical microscope (POM) was used to select a good quality single crystal for data collection.

2.5 Single crystal X-ray data collection and structure refinement

Crystals of the synthesized compounds with different shapes, which were shiny and colorless, were acquired through the slow evaporation technique at low temperatures using ethanol as the solvent. The good single-crystals of 5a, 5b, 5d, 5h, 5l, 5n, and 5p were obtained and collected at the X-ray

Table 1 Physicochemical characteristics of ethyl 3-(4-substituted benzoyl)-7-methoxyindolizine-1-carboxylate analogues (5a–p)

Code	Molecular formula	R ₁	R ₂	Yield ^{a,b} (%)	M.P. (°C)	clog P ^c
5a	C ₁₉ H ₁₇ NO ₄	H	H	79	132–134	4.3781
5b	C ₂₀ H ₁₉ NO ₄	H	CH ₃	65	125–127	4.8771
5c	C ₂₁ H ₂₁ NO ₄	H	C ₂ H ₅	68	111–113	5.4061
5d	C ₂₂ H ₂₁ NO ₆	H	CO ₂ CH ₂ CH ₃	70	126–128	3.8741
5e	C ₁₉ H ₁₆ N ₂ O ₆	NO ₂	H	64	169–172	4.2535
5f	C ₂₀ H ₁₈ N ₂ O ₆	NO ₂	CH ₃	72	160–162	4.7525
5g	C ₂₁ H ₂₀ N ₂ O ₆	NO ₂	C ₂ H ₅	66	145–147	5.2815
5h	C ₂₂ H ₂₀ N ₂ O ₈	NO ₂	CO ₂ CH ₂ CH ₃	62	184–186	3.7419
5i	C ₁₉ H ₁₆ ClNO ₄	Cl	H	75	164–166	5.0993
5j	C ₂₀ H ₁₈ ClNO ₄	Cl	CH ₃	61	122–124	5.5983
5k	C ₂₁ H ₂₀ ClNO ₄	Cl	C ₂ H ₅	67	108–110	6.1273
5l	C ₂₂ H ₂₀ ClNO ₆	Cl	CO ₂ CH ₂ CH ₃	82	148–150	4.5899
5m	C ₂₀ H ₁₉ NO ₇	CH ₃	H	68	150–152	4.8771
5n	C ₂₁ H ₂₁ NO ₄	CH ₃	CH ₃	63	112–114	5.3761
5o	C ₂₂ H ₂₃ NO ₄	CH ₃	C ₂ H ₅	60	110–112	5.9051
5p	C ₂₃ H ₂₃ NO ₆	CH ₃	CO ₂ CH ₂ CH ₃	78	162–164	4.3731

^a All the synthetic compounds were characterized by physical and spectral data. ^b Yield was calculated after column chromatography purification and confirmation. ^c ChemBioDraw Ultra 16.0v program was used to calculate clog P.

diffraction beamline (XRD1) of the Elettra Synchrotron (Trieste, Italy).³⁹ The crystal was immersed in NHV oil (Jena Bioscience, Jena, Germany) and subsequently fixed to the goniometer head with nylon loops (MiTeGen, Ithaca, USA). The complete dataset was collected at 100 K using a nitrogen stream provided by an Oxford Cryostream 700. Data were collected using a Pilatus 2M hybrid-pixel area detector (DECTRIS Ltd., Baden-Daettwil, Switzerland) with a monochromatic wavelength of 0.700 Å and employing the rotating crystal method. The diffraction data were indexed and integrated using the XDS software.⁴⁰ The structure was solved using Olex2 software,⁴¹ employing the intrinsic phasing SHELXT program⁴² for structure solution, followed by refinement using the SHELXL package,⁴³ which utilizes least-squares minimization. Mercury 4.2.0 software and the POV-Ray program were utilized to generate the molecular graphics and images.^{44,45} Geometric calculations and the generation of the hydrogen bond table were performed using the PLATON program.⁴⁶ Hydrogen atoms in all **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p** compounds were located from the diffraction maps. The C–H bond distances were constrained to 0.95 Å for CH groups, 0.99 Å for CH₂ groups, and 0.98 Å for CH₃ groups. The structure was refined to *R* factors of 0.0423, 0.0359, 0.0368, 0.0470, 0.035, 0.0429, and 0.0374 for compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p** respectively. Refinement factors and crystallographic data for the compound discussed, along with CIF files deposited at the Cambridge Crystallographic Data Centre (CCDC), are mentioned in Table S1.†

2.6 Hirshfeld surface analysis

The Hirshfeld surface at the molecular level is built around a spherical atom using electron density distribution.^{47,48} The uniqueness of the Hirshfeld surface lies in its association with a specific crystal structure and a defined set of spherical atomic electron densities. This characteristic suggests the possibility of gaining additional insight into the intermolecular interactions in molecular crystals.⁴⁹ On Hirshfeld surfaces, the distances d_e and d_i represent the distances from the surface to the external nucleus and from the surface to the internal nucleus, respectively. The 2D fingerprint plot, formed by combining d_e and d_i , summarizes intermolecular contacts within the crystal.⁵⁰ The Hirshfeld surfaces, including d_{norm} , d_i , d_e , shape index, curvedness, and two-dimensional (2D) fingerprint plots, were generated using the Crystal Explorer 21.5 software to visualize the intermolecular interactions within these molecules.^{51,52}

2.7 Energy framework analysis

An energy framework analysis was employed to graphically depict the nature of the energy associated with the short interaction within the crystal structure. The energy framework provides a qualitative description of the three-dimensional topology of the associated interaction present within the crystal structure, which was carried out using

Crystal Explorer 21.5.^{52,53} This approach provides an understanding of intermolecular interaction energy and their corresponding partitioned energy through 3D-graphical representations. The energy framework analysis was performed using the B3LYP method with the 6-31G(d,p) basis set.

2.8 Computational analysis

Density functional theory (DFT) calculations were performed using the GAUSSIAN 09 program for the synthesized compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**.⁵⁴ The molecular structures of the compounds were derived from single-crystal X-ray crystallographic data. The single point energy calculations were executed using the B3LYP method with the 6-311G(d,p) basis set.⁵⁵ The results were visualized using the GAUSS VIEW 6.0 program. The reactivity parameters for the mentioned compounds were derived from the FMO analysis. Additionally, MEP surfaces were generated to identify potential active sites involved in non-covalent interaction formation.⁵⁶ Furthermore, essential tools such as NCI and QTAIM analyses were utilized to assess the strength and qualitative and quantitative nature of HBs present within the molecular assembly of these compounds using the Multiwfn 3.6 package,⁵⁷ with results visualized using VMD.⁵⁸

2.9 Anti-tubercular activity

The designed compounds (**5a–p**) were assessed for their ability to combat tuberculosis by testing their activity against three different types of MTB strains, specifically H37Rv, MDR, and XDR strains. This evaluation was conducted using the resazurin microplate assay (REMA) method, which utilizes colorimetric measurements.⁵⁹ A 100 µL portion of Middlebrook 7H9 broth prepared and administered aseptically was placed in each 96-well flat-bottomed microtiter plate with covers (Lasec, South Africa). The test compounds were precisely measured, dissolved in a suitable solvent, and subjected to filter sterilization with a 0.2-micron polycarbonate filter to ensure accuracy. The test samples were divided into smaller portions and placed in cryovials before storing at –20 °C. Then, 100 µL of each test sample was introduced into the wells containing Middlebrook 7H9 broth. The broth was enriched with 0.1% casitone, 0.5% glycerol, and 10% OADC, which stands for oleic acid, albumin, dextrose, and catalase. The test samples were diluted stepwise, with each dilution being two times weaker than the previous one, directly in the microtiter plate's broth. This process resulted in a range of desired concentrations from 40–0.625 µg mL^{–1}.

Fresh inoculums were prepared from clinical isolates obtained from Middlebrook 7H11 agar plates. The process involved scraping a loopful of colonies and re-suspending them into Middlebrook 7H9 broth containing glass beads. The initial density of the inoculum was calibrated to match the McFarland number 1 standard. Afterwards, it was further diluted in M7H9 broth at a ratio of 1:10. Subsequently, 100

μL of this diluted inoculum was added to both the test samples and wells without any drugs. Each isolate was accompanied by a growth control and a sterile control. To prevent evaporation during incubation, the sterile M7H9 broth was added to the perimeter wells. The plate was securely covered and placed inside a plastic bag before being placed in an incubator at 37°C . Following an incubation period of 8 days, a volume of $30\ \mu\text{L}$ from a 0.02% working solution of resazurin salt was introduced into each microtiter well. After incubating the plates overnight, they were examined the next day. A color change from blue to pink indicated a positive reaction, indicating the reduction of resazurin to resorufin. This confirmed the viability and growth of MTB cells and, consequently, their drug resistance. The MICs were determined by identifying the lowest concentration of the drug that prevented the organism's growth without observing any color changes in the well.

2.10 Safety studies (*in vitro*)

The safety of the tested indolizines was evaluated using an MTT assay. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity assay was used to evaluate the cytotoxic effect of the most promising compounds against peripheral blood mononuclear cells (PBMCs) according to the described protocol.⁶⁰ Cells were pipetted ($90\ \mu\text{L}$ of cell culture, 1×10^5 cells per mL) into each well of 96-well microtiter plates, and the outer wells were filled with PBS (phosphate buffered saline) to prevent the medium from evaporation during incubation. After that, plates were incubated at 37°C for 24 h. Each well of the plate was then treated with $10\ \text{mL}$ of the compounds ($1000\text{--}5\ \text{mg mL}^{-1}$). In the control wells, the negative control DMSO (dimethyl sulfoxide) and media were added. The plates were incubated for 2 days at 37°C in a humidified incubator that contained a 5% CO_2 atmosphere. After the incubation, $20\ \text{mL}$ of MTT reagent ($5\ \text{mg mL}^{-1}$) was added to the individual well. The plate was then incubated for 4 h at 37°C (5% CO_2 incubator). The media was then removed, and an aliquot of $100\ \mu\text{L}$ DMSO was added to each well to dissolve the formazan crystals formed in metabolically active cells. After that, the plates were incubated for an extra hour. The absorbance of the formazan was evaluated at $590\ \text{nm}$ using an ELISA plate reader (Thermo Scientific Multiskan GO).

3. Results and discussion

3.1 Spectroscopic data

The FT-IR spectra of the ethyl 3-(4-substituted benzoyl)-7-methoxyindolizine-1-carboxylate compounds showed the aromatic C–H stretching frequency $\sim 3150\text{--}3000\ \text{cm}^{-1}$. The C–H aliphatic stretching frequency of the methyl and methylene groups was observed at the regions of $2990\text{--}2950\ \text{cm}^{-1}$ and $2870\text{--}2840\ \text{cm}^{-1}$, respectively. Also, the carbonyl functional stretching frequency of the ester group was observed at $1720\text{--}1700\ \text{cm}^{-1}$, and the aromatic C=N stretching frequency was observed in the $1340\text{--}1320\ \text{cm}^{-1}$

region. *para*-Substituted compounds showed their stretching frequency at $810\text{--}790\ \text{cm}^{-1}$ (Fig. S3†). In the ^1H -NMR spectrum, the fused heteroaromatic ring protons of the indolizine ring have appeared at 7.55 to $7.52\ \text{ppm}$, and the ester CH_2 protons have appeared at 4.29 to $4.27\ \text{ppm}$. Further, the CH_3 protons attached to the heteroatom oxygen, which is a part of the indolizine moiety, appeared at 3.93 to $3.89\ \text{ppm}$, and ester CH_3 protons appeared at 1.36 to $1.33\ \text{ppm}$. The ^1H and ^{13}C -NMR spectra of respective indolizine derivatives are mentioned in the ESI† (Fig. S4–S5).

3.2 Single crystal structure X-ray diffraction analysis

The synthesized compounds **5a**, **5d**, **5l**, and **5p** crystallize in the triclinic crystal system with the space group $P\bar{1}$ whereas **5b**, **5h**, and **5n** crystallize in the monoclinic crystal system with the space group $P2_1/c$. The respective lattice parameters and other crystallographic information for the mentioned compounds are provided in Table S1†. The molecular structures of the seven crystals are depicted in Fig. 1. The molecular packing of these compounds in the solid state is mostly influenced by the weak C–H \cdots O hydrogen bonding along with the additional C–H $\cdots\pi$ hydrogen bonding interactions (Fig. 2 and S37 and Table S2†). Prominent intra- and inter-molecular H-bonding interactions associated with these reported compounds are depicted in Table 2.

Crystal structure and packing of 5a. The compound **5a** crystallizes in the triclinic space group $P\bar{1}$ with two molecules in the unit cell ($Z = 2$) and one in the asymmetric unit ($Z' = 1$). It forms a ring dimer with a $R_2^2(14)$ graph-set motif *via* C2–H2 \cdots O3 [$2.501(1)\ \text{\AA}$, $156.1(1)^\circ$] hydrogen bonding interactions. Meanwhile, other C–H \cdots O interactions [$2.586(2)\ \text{\AA}$, $132.8(1)^\circ$] propagate along the *ab*-plane in the crystal




Fig. 1 Molecular structures of **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p** with anisotropic displacement ellipsoids drawn at the 50% probability level. Intramolecular hydrogen bonds are drawn as dotted lines, and H-atoms not involved in interactions are omitted for clarity.




Fig. 2 The molecular assembly of **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p** through dimer motifs and other weak C—H \cdots O interactions.

structure (Fig. 2, Table 2). Additionally, C–H $\cdots\pi$ interactions [π = Cg, C8–H8B \cdots Cg1, 2.862(1) Å, 160.7(1)°] between the methylene group of the ester and the indolizine moiety (Fig. S37, Table S2†), as well as $\pi\cdots\pi$ (Cg=Cg) interactions [Cg2 \cdots Cg2, 3.621(9) Å], stabilize the molecular assembly (Fig. S38, Table S3†).

Crystal structure and packing of 5b. The compound **5b** crystallizes in the monoclinic space group $P2_1/c$ with four molecules in the unit cell ($Z = 4$) and one in the asymmetric unit ($Z' = 1$). Its molecular assembly prefers the formation of two dimers with $R_2^2(12)$ and $R_2^2(20)$ graph-set motifs by C–H \cdots O [C1–H1 \cdots O3, 2.478(1) Å, 126.7(1)°; C15–H15 \cdots O4, 2.495(1) Å, 155.7(1)°] hydrogen bonding interactions (Fig. 2, Table 2). Further the methylene group of the ester engages C–H $\cdots\pi$ interaction with the indolizine and benzoyl moieties which stabilized the crystal packing [C8–H8A \cdots Cg1, 2.954(1) Å, 128.3(8)°, C20–H20A \cdots Cg3, 2.973(1) Å, 143.7(9)°] (Fig. S37, Table S2†). In addition, the $\pi\cdots\pi$ interaction [Cg1 \cdots Cg2, 3.778(9) Å] stabilizes the molecular assembly (Fig. S38, Table S3†).

Crystal structure and packing of 5d. The compound **5d** crystallizes in the triclinic space group $P\bar{1}$ with two molecules in the unit cell ($Z = 2$) and one molecule in the asymmetric unit ($Z' = 1$). The ring dimer with a $R_2^2(10)$ graph-set motif is stabilized by C1–H1 \cdots O5 [2.390(1) Å, 127.5(9)°] hydrogen bonding interactions (Fig. 2, Table 2). The methylene group of the ester forms C–H $\cdots\pi$ interaction with both the indolizine and benzoyl moieties to stabilize this molecular assembly [C9–H9A \cdots Cg3, 2.927(1) Å, 155.2(1); C9–H9C \cdots Cg1, 2.882(1) Å, 166.9(1); C13–H13B \cdots Cg3 2.788(1) Å, 132.0(1), (Fig. S37, Table S2†). Moreover, the crystal packing is stabilized by $\pi\cdots\pi$ interaction [Cg2 \cdots Cg2, 3.559(7) Å] (Fig. S38, Table S3†).

Crystal structure and packing of 5h. The compound **5h** crystallizes in the monoclinic space group $P2_1/c$ with eight molecules in the unit cell and two molecules in the asymmetric unit cell ($Z = 8$, $Z' = 2$). The molecule exhibits several weak C–H \cdots O hydrogen bonds, namely C2B–H2B \cdots O5A [2.519(2) Å, 169.0(2)°], C9A–H9A2 \cdots O1B [2.573(2) Å, 154.0(2)°] and C22B–H22F \cdots O3B [2.521(2) Å, 140.2(2)°] in their crystal packing (Fig. 2, Table 2). Unlike other crystal structures, none of these C–H \cdots O interactions form dimers. However, the methylene group of the ester forms C–H $\cdots\pi$ interactions with the indolizine moiety, specifically C12A–H12A \cdots Cg1 [2.876(2) Å, 146.6(1)°], C12A–H12A \cdots Cg2 [2.901(2) Å, 151.7(1)°], and C13B–H13F \cdots Cg8 [2.961(3) Å, 170(2)°] interactions (Fig. S37, Table S2†). Additionally, a $\pi\cdots\pi$ interaction [Cg1 \cdots Cg2, 3.586(1) Å] contributes to the stabilization of the molecular assembly (Fig. S38, Table S3†).

Crystal structure and packing of 5l. The compound **5l** crystallizes in the triclinic space group $P\bar{1}$ with two molecules in the unit cell and one molecule in the asymmetric unit cell ($Z = 2$, $Z' = 1$). The crystal structure shows a ring dimer with a $R_2^2(10)$ graph-set motif self-assembled by C8–H8B···O1 [2.537(1) Å, 164.0(1)°] hydrogen bonds along with other C–H···O interactions (Fig. 2, Table 2). In addition, the crystal packing is consolidated by C–H··· π interaction through the methylene group of the ester with the indolizine moiety such as C13–H13C···Cg1 [2.787(2) Å, 154.0(1)°] and C13–H13C···Cg2 [2.970(2) Å, 130.0(2)°] (Fig. S37, Table S2†). Furthermore, the molecular assembly is stabilized through π ··· π interactions [Cg1···Cg2, 3.790(9) Å; Cg2···Cg2, 3.842(9) Å] (Fig. S38, Table S3†).

Crystal structure and packing of 5n. The compound **5n** crystallizes in the monoclinic space group $P2_1/c$ with two molecules in the unit cell and one in the asymmetric unit ($Z = 2$, $Z' = 1$). The crystal structure is stabilized by C–H···O interactions, without the formation of dimers as seen in other structures [C16–H16···O3, 2.524(2) Å, 153.1(1)°] and [C19–H20B···O1, 2.473(2) Å, 170.5(1)°] (Fig. 2, Table 2). In addition to this, C–H··· π interactions [C11–H11B···Cg1, 2.915(1) Å, 113.4(1)°] between the methylene group of the ester and the indolizine moiety (Fig. S37, Table S2†), along with a π ··· π interaction [Cg1···Cg2, 3.483(9) Å], stabilize the molecular assembly (Fig. S38, Table S3†).

Crystal structure and packing of 5p. The synthesized compound **5p** crystallizes in the triclinic space group $P\bar{1}$ with two molecules in the unit cell ($Z = 2$) and one in the asymmetric unit ($Z' = 1$). The crystal structure is established through the C–H \cdots O hydrogen bond dimer with a $R_2^2(10)$ graph-set motif [C8–H8B \cdots O1, 2.495(1) Å, 165.1(1) $^\circ$] and the C–H \cdots O hydrogen bond propagated along the a -axis [C2–H2 \cdots O1, 2.284(2) Å, 157.5 (1) $^\circ$] (Fig. 2, Table 2). This molecular assembly also prefers C–H $\cdots\pi$ interaction through the methylene group of the ester with the indolizine moiety [C13–H13B \cdots Cg1, 2.771(2) Å, 153.5(1) $^\circ$] (Fig. S37, Table S2 †) and $\pi\cdots\pi$ interactions [Cg1 \cdots Cg2, 3.863(9) Å; Cg1 \cdots Cg2, 3.863(9) Å] (Fig. S38, Table S3 †) stabilized the molecular assembly for effective crystal packing.

Table 2 The prominent intra and inter-molecular H-bonding interactions are associated with the compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**

Code	Intra and inter-molecular H-bonding interactions				
	D–X···A	D–X (Å)	X···A (Å)	D···A (Å)	<D–X···A (°)
5a	C1–H1···O3	0.917(1)	2.246(2)	2.884(1)	126.2(1)
	C4–H4···O1	0.966(1)	2.501(1)	3.064(1)	117.1(1)
	C2–H2···O3 ⁱ	0.978(2)	2.281(2)	3.199(1)	156.1(1)
	C16–H16···O1 ⁱⁱ	0.977(2)	2.586(2)	3.326(1)	132.8(1)
	Symmetry codes: (i) 2 – x, 1 – y, –z; (ii) 1 + x, –1 + y, z				
5b	C1–H1···O3	0.939(1)	2.179(1)	2.829(1)	125.5(1)
	C4–H4···O2	0.966(1)	2.359(1)	2.922(1)	116.7(8)
	C11–H11B···O1	0.991(1)	2.467(1)	2.926(1)	107.8(9)
	C1–H1···O3 ⁱ	0.939(1)	2.478(1)	3.130(1)	126.7(1)
	C8–H8B···O3 ⁱⁱ	0.963(1)	2.398(1)	3.288(1)	153.5(1)
	C15–H15···O4 ⁱⁱⁱ	0.989(1)	2.495(1)	3.420(1)	155.7(1)
	Symmetry codes: (i) –x, 2 – y, –z; (ii) 1 + x, y, z; (iii) 1 – x, 2 – y, –z				
5d	C1–H1···O5	0.940(1)	2.267(1)	2.878(1)	121.0(9)
	C4–H4···O2	0.931(1)	2.399(1)	2.945(1)	116.5(9)
	C1–H1···O5 ⁱ	0.957(1)	2.390(1)	3.068(1)	127.5(9)
	Symmetry codes: (i) –1 – x, 1 – y, 1 – z				
5h	C1B–H1B···O5B	0.981(2)	2.269(2)	2.861(2)	122.7(1)
	C4B–H4B···O1B	0.977(2)	2.497(2)	3.029(2)	117.8(1)
	C2B–H2B···O5A ⁱ	0.98(2)	2.519(2)	3.459(3)	169.0(2)
	C9A–H9A2···O1B ⁱⁱ	0.98(2)	2.573(2)	3.484(4)	154.0(2)
	C17B–H17B···O4A ⁱⁱⁱ	0.956(2)	2.600(2)	3.484(2)	158.6(2)
	C18A–H18A···O6A ^{iv}	1.006(2)	2.533(2)	3.115(2)	117.8(1)
	C22A–H22B···O7B1 ^v	1.008(2)	2.489(2)	3.453(2)	164.1(2)
	C22A–H22B···O3B ^{vi}	0.99(2)	2.540(2)	3.478(2)	159.1(2)
	C22B–H22F···O3B ^{vii}	1.02(2)	2.521(2)	3.363(2)	140.2(2)
	C22B–H22E···O7A1 ^{viii}	0.98(2)	2.524(2)	3.486(2)	163.3(2)
	Symmetry codes: (i) 1/2 – x, –1/2 + y, 1/2 – z; (ii) –1/2 + x, 1/2 – y, 1/2 + z; (iii) 1 + x, y, z; (iv) –1 + x, y, z; (v) –1 + x, y, z; (vi) –1/2 + x, 1/2 – y, 1/2 + z; (vii) –1 + x, y, z; (viii) 1 + x, y, z				
5l	C1–H1···O5	0.939(2)	2.244(1)	2.896(1)	126.0(1)
	C4–H4···O2	0.933(1)	2.355(2)	2.904(1)	117.4(1)
	C2–H2···O1 ⁱ	0.970(2)	2.282(2)	3.194(2)	156.5(1)
	C8–H8B···O1 ⁱⁱ	0.952(1)	2.537(1)	3.462(1)	164.0(1)
	C22–H22B···O3 ⁱⁱⁱ	0.963(2)	2.574(2)	3.222(1)	124.9(1)
	Symmetry codes: (i) –1 + x, y, z; (ii) 1 – x, –y, 1 – z; (iii) x, y, 1 + z				
5n	C1–H1···O3	0.952(1)	2.262(1)	2.832(1)	117.7(1)
	C4–H4···O2	0.969(2)	2.337(1)	2.889(1)	115.4(1)
	C11–H11B···O1	0.987(1)	2.457(2)	2.943(1)	110.0(9)
	C16–H16···O3 ⁱ	0.973(2)	2.524(2)	3.420(1)	153.1(1)
	C19–H20B···O1 ⁱⁱ	0.979(2)	2.473(1)	3.4425(2)	170.5(1)
	Symmetry codes: (i) x, 1/2y, 1/2 + z; (ii) x, –1/2 – y, –1/2 + z				
5p	C1–H1···O5	0.951(1)	2.262(1)	2.895(1)	123.3(1)
	C4–H4···O2	0.941(1)	2.361(1)	2.913(13)	117.2(1)
	C2–H2···O1 ⁱ	0.977(2)	2.284(1)	3.208(14)	157.5(1)
	C8–H8B···O1 ⁱⁱ	0.972(1)	2.495(1)	3.443(12)	165.1(1)
	Symmetry codes: (i) –1 + x, y, z; (ii) 1 – x, –y, 1 – z				

In summary, it is interesting to note that the crystal structures of **5a**, **5b**, **5d**, **5l**, and **5p** prefer C–H···O hydrogen bond dimers, except **5n** and **5h**. It is also noteworthy that the phenyl-substituted derivatives (**5a**, **5b**, and **5d**) prefer a different type of dimer formation *via* C–H···O hydrogen bonds, which may be influenced by the R₂ substituents. The indolizine derivatives, such as the *p*-nitrophenyl derivative (**5h**) and the *p*-toluene derivative (**5n**), prefer non-dimeric C–H···O interactions in their crystal packing. Furthermore, it is observed that the crystal structures of all the indolizine derivatives (**5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**) favour C–H···π interactions between the methylene-ester moiety of the hydrogen atom and the indolizine ring. In contrast, the crystal structures of **5b** and **5d** exhibit an additional C–H···π

interaction involving the methylene-ester moiety and the benzoyl group. Additionally, compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**, exhibit π···π (Cg···Cg) stacking interactions, which play a crucial role in the crystal packing (Fig. S38, Table S3†).

3.3 HS investigation and 2D fingerprint plots

The HS of the single-crystal structures was analyzed with respect to d_{norm} , d_i , d_e , shape index, and curvedness to illustrate the characteristics of intermolecular interactions (Fig. 3). In the d_{norm} surfaces, red and blue areas denote shorter and longer contacts compared to the van der Waals radii, respectively, with white indicating contacts close to the




Fig. 3 Surfaces have been drawn over a) d_{norm} (front and back view), b) d_i , c) d_e , d) shape-index, and e) curvedness for the compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**.

van der Waals radii. Additionally, the red spots (labelled 1) on the d_{norm} surfaces indicate existing hydrogen bonding $\text{H}\cdots\text{O}$ interactions and contribute to the formation of dimers in specific crystal structures (Fig. S39[†]). Meanwhile, the areas labelled 2, especially in **5a**, **5b**, **5d**, **5l**, **5n** and **5p**, suggest the $\text{C}\cdots\text{H}$ interaction sites. Similarly, the light red spots (labelled 3) reveal the presence of $\text{C}\cdots\text{C}$ interactions, which may be associated with $\pi\cdots\pi$ interactions in the crystal packing. In contrast, the blue regions (labelled 4) indicate $\text{H}\cdots\text{H}$ interactions (Fig. 3(a)). The d_e and d_i surfaces represent the distances from the HS to the closest nuclei inside and outside the surface, respectively (Fig. 3(b) and (c)). Further, the shape index and curvedness surface analysis was carried out to investigate the $\pi\cdots\pi$ ($\text{Cg}\cdots\text{Cg}$) interactions present in the system.^{61,62} The presence of red triangles in concave regions and blue triangles in convex regions as highlighted by the black circle on the shape index surface provides evidence of the $\pi\cdots\pi$ stacking and aromatic ring index, respectively (Fig. 3(d)). The HS, when mapped with curvedness, reveals flat regions outlined in blue, highlighting the contributions of the rings in $\pi\cdots\pi$ stacking interactions (Fig. 3(e)). Further, the 2D fingerprint plot depicted the percentage distribution of various interactions within the molecule, highlighting the presence of short contacts (Fig. S40(a)[†]). The 2D plot indicates that $\text{H}\cdots\text{H}$ interactions make up the highest contribution to the overall interactions *i.e.*, 55.5%, 53.4%, 50.7%, 49.1%, 45.9%, 37.7%, and 35.4% in **5n**, **5b**, **5p**, **5a**, **5d**, **5l**, and **5h**, respectively. Conversely, the contribution of $\text{H}\cdots\text{O}$ contact is relatively higher in **5h** and **5d** (33.0%, 27.6%) compared to **5a** (18.3%), **5b** (17.9%), **5l** (24.5%), **5n** (18.0%), and **5p** (24.7%) on the HS (Fig. S40(b)[†]). Additionally, the contribution of $\text{C}\cdots\text{C}$ interactions to the

total interactions is 2.2%, 5.0%, 1.4%, 2.7%, 3.3%, 5.1%, and 3.2% in **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**, respectively, indicating the existence of $\pi\cdots\pi$ stacking within the compounds (Fig. S38[†]), as explained by the crystal structure analysis. The HS and 2D plots of compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p** are in good agreement with the previously reported similar indolizine derivatives.^{9,35,63}

3.4 Energy framework calculation

The energy framework calculation was carried out to construct the three-dimensional topology of interactions within a supramolecular structure. The scaling factors employed in generating electron densities for compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p** are as reported by Mackenzie *et al.*^{64,65} (Table S4[†]). The cut-off value for the threshold energy was set at 0 kJ mol^{-1} , and the tube size was maintained at 100 in all energy frameworks. The interaction energies between molecular pairs are represented by cylinders connecting the molecules, with the cylinder radii proportional to the strength of these intermolecular interactions. The interaction energies between selected molecules within the cluster, formed around a single molecule at a radius of 3.8 Å with unit cell dimensions of $1 \times 1 \times 1$, were analyzed. The visualizations of various energies like total interaction, dispersion, and electrostatic (coulombic) energies are depicted by blue, green, and red colored cylinders, respectively (Fig. S43[†]).

These energies with color-coded molecular pairs are illustrated in Fig. S41 and Tables S5–S11.[†] The total interaction energies for compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p** are $-235.5 \text{ kJ mol}^{-1}$, $-288.1 \text{ kJ mol}^{-1}$, $-300.3 \text{ kJ mol}^{-1}$, $-356.3 \text{ kJ mol}^{-1}$, $-305.2 \text{ kJ mol}^{-1}$, $-191.5 \text{ kJ mol}^{-1}$, and $-319.7 \text{ kJ mol}^{-1}$, respectively. Further, in all the compounds (**5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**) the dispersion energy predominates over the electrostatic energy and has a major contribution to the total interaction energy, similar to the energy frameworks of reported indolizine derivatives.^{9,35,63} Notably, the addition of an extra ester moiety leads to an increase in the total interaction energy. In addition, electron-withdrawing groups like NO_2 and Cl also raise the total interaction energy in these indolizine systems (Table S12[†]). Fig. S42[†] illustrates the d_{norm} mapped on the HS for the central molecule and energy frameworks.

3.5 Computational analysis

3.5.1. FMOs analysis and global reactivity descriptors. The HOMO–LUMO energy gap is useful for determining the electronic arrangements of a molecule and plays a crucial role in analyzing its chemical reactivity.^{66,67} Further, the global chemical reactivity descriptors were calculated utilizing Koopmans' theorem.⁶⁸ The positive phase is depicted in red in the three-dimensional orbital plots, while the negative phase is represented in green. In compounds **5a**, **5b**, **5d**, **5h**, **5l**, **5n**, and **5p**, the HOMO electron cloud basically covers the indolizine ring, whereas the LUMO electron cloud




Fig. 4 Frontier molecular orbital (energy gap between bottom: HOMO, top: LUMO) of compounds 5a, 5b, 5d, 5h, 5l, 5n, and 5p.

is distributed over the indolizine and benzoyl ring (for 5a, 5b, 5d, 5l, 5n and 5p) except for 5h where the LUMO electron cloud covers majorly the benzoyl ring, which may be due to the presence of more electron withdrawing nitro group. This represents a shifting of the electron cloud from the indolizine moiety to the benzoyl ring during the HOMO–LUMO transition (Fig. 4).

Furthermore, the energy gap ($\Delta E = E_{\text{LUMO}} - E_{\text{HOMO}}$) can also be used to define the stability and reactivity of synthesized compounds. Table S13† presents the HOMO and LUMO values for compounds 5a, 5b, 5d, 5h, 5l, 5n, and 5p, along with the energy gaps and global chemical reactivity descriptors. Among the compounds, 5a has the largest energy gap, while 5h has the smallest. The high value for 5a indicates its high dynamic stability and being less prone to electron transition. The negative chemical potential (μ) values observed for compounds 5a, 5b, 5d, 5h, 5l, 5n, and 5p suggest that they do not spontaneously disintegrate into their constituents.⁶⁹ The compound 5h exhibits maximum chemical softness (S), indicating its high polarizability, which is further evidenced by its low chemical hardness (η) value.

3.5.2. MEP surface analysis. The molecular electrostatic potential (MEP) surface is crucial for identifying and determining the reactive sites of the compounds for electrophilic or nucleophilic attacks. The MEP produces three-dimensional potential maps showing the isoelectron density surface of the molecule. The MEP maps for compounds 5a, 5b, 5d, 5h, 5l, 5n, and 5p were generated, where red color denotes the most significant negative charge, highlighting a favourable site for an electrophilic attack. Conversely, blue color signifies the most significant positive charge, making it more susceptible to nucleophilic attack (Fig. 5). The reddish yellow regions (related to negative potential) over the carbonylic oxygen atoms in the above-




Fig. 5 The depiction of the molecular electrostatic potential for compounds 5a, 5b, 5d, 5h, 5l, 5n, and 5p.

mentioned compounds, with an additional region over oxygen atoms of the nitro group in 5h, indicate the possible sites for non-covalent interactions like weak hydrogen bonding.

3.5.3. Non-covalent interactions analysis. The reduced density gradients (RDGs) with low electron densities are basically associated with regions exhibiting weak non-covalent interactions (NCIs). Therefore, in order to assess and identify the regions implicated in the weak interactions in a molecular system, the NCI analysis utilizes the RDG values. The non-covalent interactions, especially HB interactions, can be effectively examined through NCI analysis. The plot of reduced density gradient (RDG) versus $\text{sign}(\lambda_2)\rho(r)$ elucidates the nature of such interactions. The bonded interactions have $\lambda_2 < 0$, while non-bonded interactions have $\lambda_2 > 0$. The 2D plots for compounds 5a, 5b, 5d, 5h, 5l, 5n, and 5p reveal that the intra-molecular hydrogen bonding interactions have $\text{sign}(\lambda_2)\rho(r)$ values ranging from -0.010 to -0.018 a.u. (Fig. 6). In contrast, the intermolecular hydrogen bonding interactions are comparatively weaker, which is evident from the $\text{sign}(\lambda_2)\rho(r)$ values around -0.006 to -0.013 a.u. (Fig. S44†). Further, the presence of the green isosurface between O and H atoms in the 3D plot suggests the HB formation. In summary, these C–H \cdots O HB interactions have $\text{sign}(\lambda_2)\rho(r)$ values in the range of -0.006 a.u. to -0.018 a.u., which suggests their weak nature.

3.5.4. QTAIM analysis. HBs can be described qualitatively and quantitatively by quantum theory of atoms in molecules (QTAIM) analysis based on the topological investigation of




Fig. 6 2D NCI plots (on the left) and 3D gradient isosurfaces (on the right) depict intra-molecular HB interactions within compounds 5a, 5b, 5d, 5h, 5l, 5n, and 5p.

electron density, proposed by Bader,⁷⁰ which resulted in bond critical points (BCPs) and bond paths (BPs) for these interactions present in the crystal packing of the compounds 5a, 5b, 5d, 5h, 5l, 5n, and 5p (Fig. 7 and 8). The existence of HB interactions is clearly indicated by the (3; -1) BCPs along the H...O bond paths (BPs) in the systems. The electron density ($\rho(r)$) values at the BCPs of these HB interactions fall within the acceptable range of 0.002–0.035 a.u. Additionally, the positive values of the Laplacian of electron density ($\nabla^2\rho(r)$) indicate the depletion of electronic charge along the interatomic path. Furthermore, the ratios of the absolute potential energy




Table 3 *In vitro* anti-tubercular activity of ethyl 7-methoxy-3-(4-substituted benzoyl)indolizine-1-carboxylate derivatives (**5a–p**) against H37Rv (susceptible), MDR and XDR strains of MTB

Entry	R ₁	R ₂	MIC ($\mu\text{g mL}^{-1}$)		
			H37Rv ^a (susceptible)	MDR-MTB ^b	XDR
5a	H	H	8	8	NA
5b	H	CH ₃	16	16	NA
5c	H	C ₂ H ₅	16	16	NA
5d	H	CO ₂ CH ₂ CH ₃	32	32	64
5e	NO ₂	H	4	16	16
5f	NO ₂	CH ₃	8	16	16
5g	NO ₂	C ₂ H ₅	16	16	NA
5h	NO ₂	CO ₂ CH ₂ CH ₃	8	8	64
5i	Cl	H	NA	NA	NA
5j	Cl	CH ₃	NA	NA	NA
5k	Cl	C ₂ H ₅	NA	NA	NA
5l	Cl	CO ₂ CH ₂ CH ₃	16	16	64
5m	CH ₃	H	NA	NA	NA
5n	CH ₃	CH ₃	8	8	128
5o	CH ₃	C ₂ H ₅	NA	NA	NA
5p	CH ₃	CO ₂ CH ₂ CH ₃	16	16	NA

^a American Type Culture Collection (ATCC): 25177. ^b These isolates were found to be resistant to the first line of antibiotics, rifampicin ($1 \mu\text{g mL}^{-1}$), and isoniazid ($0.2 \mu\text{g mL}^{-1}$). Abbreviations: MDR-MTB, multidrug-resistant and XDR, extensively drug-resistant strains of *Mycobacterium tuberculosis*; MIC, minimum inhibitory concentration; NA, not active at the concentration range (0.2 – $128 \mu\text{g mL}^{-1}$).

remarkable anti-tubercular activity. It displayed the most potent inhibitory effect against the drug susceptible H37Rv MTB strain, with a minimum inhibitory concentration (MIC) value of $4 \mu\text{g mL}^{-1}$. Four compounds (**5a**, **5f**, **5h**, and **5n**) exhibited equal potency, displaying a minimum inhibitory concentration (MIC) value of $8 \mu\text{g mL}^{-1}$ against the H37Rv MTB strain. Compounds **5b**, **5c**, **5g**, **5l**, and **5p** demonstrated significant anti-TB activity with an MIC value of $16 \mu\text{g mL}^{-1}$ against the same strain. Compound **5d** displayed a moderate level of anti-TB activity, showing a MIC value of $32 \mu\text{g mL}^{-1}$ against the H37Rv MTB strain. On the other hand, no activity was observed for the remaining indolizines when tested against the H37Rv MTB strain.

The current study revealed that the presence of a hydrogen, methyl, ethyl, or an ester substituent at the 2-position of the indolizine ring was favourable for attaining good antitubercular activity. Compounds featuring hydrogen and nitro groups at the *para* position of the benzoyl ring exhibited significant activity against H37Rv and MDR-MTB strains. However, methyl or chloro groups abolished activity for compounds **5i**, **5j**, **5k**, **5m**, and **5o** against all strains. While most compounds were inactive against XDR-MTB, **5d**, **5e**, **5f**, **5h**, **5l**, and **5n** retained moderate activity, suggesting that they target different MTB molecular sites. For phenyl derivatives, compounds **5a** (hydrogen), **5b** (methyl), and **5c** (ethyl) at the 2-position of the indolizine ring showed 4-fold and 2-fold greater activity compared to the compound **5d** (ester). Similarly, for nitro derivatives, compounds **5e** (hydrogen), **5f** (methyl), and **5h** (ester) exhibited 4-fold and 2-fold higher activity than **5g** (ethyl) at the same position.

The structural alteration of the indolizine scaffold at 1- and 2-positions had a notable impact on the efficacy of the

compound against various strains of MTB, including H37Rv, MDR, and XDR strains. The indolizine derivatives **5a–5h**, **5l**, **5n**, and **5p** were active against H37Rv and MDR-MTB but inactive against XDR-MTB, except for compounds **5d**, **5e**, **5f**, **5h**, **5l**, and **5n** (Table 3). The compounds **5d**, **5h**, and **5l** with an ethyl ester group at the 2-position of the indolizine ring for phenyl, nitro, and chloro derivatives showed moderate activity against XDR-MTB, with 2-fold, 4-fold and 8-fold decrease in potency, respectively, as compared with the cellular activity against susceptible H37Rv MTB strain. However, compounds **5e** and **5f** of nitro derivatives showed similar activity against MDR and XDR-TB strains, but decreased in 4-fold and 2-fold potency compared with the cellular activity against the susceptible H37Rv MTB strain. The anti-tubercular activity profile of the tested compounds against MDR and XDR-MTB provided a clue for their mode of action. Indeed, the results demonstrated that the series of indolizine derivatives (**5a–p**) did not show activity against XDR-TB except for compounds **5d–5f**, **5h**, **5l**, and **5n**. In contrast, the series of compounds (**5a–p**) show good inhibition growth of H37Rv and MDR-MTB strains except for **5i–5k**, **5m**, and **5o**. These findings and observations suggest that the series of indolizine derivatives are likely to inhibit different MTB molecular drug targets; such that the phenyl, chloro, and methyl derivatives of indolizine inhibit a common target that is different from that inhibited by the nitro derivatives. On the other hand, the nitro derivatives of the compounds that demonstrated activity against the XDR-TB strain could potentially engage with the identical molecular target as the phenyl, chloro, and methyl derivatives of indolizine. However, their interaction with the binding site of the target might differ.

3.7 ADME and toxicity study

All the potent compounds (**5a–p**) were subjected to ADME and toxicity predictions using SwissADME with pkCSM. Evaluation of a molecule's fate in the human body involves assessing its ADME (absorption, distribution, metabolism, and elimination) properties. Physicochemical and biopharmaceutical parameters were calculated to estimate the ADME parameters of the identified compounds. Analysis of the physicochemical features revealed that the molar refractivity ranged from 89.85 to 110.90, falling within the acceptable range (30–140). The topological polar surface area (TPSA) plays a critical role in balancing the lipophilicity and hydrophilicity of a drug candidate, ensuring that it meets optimal ADMET requirements for efficacy and safety. The TPSA ranged from 57.01 to 129.13 Å², suggesting that the molecules tend to have better oral bioavailability, as they can more easily cross cell membranes *via* passive diffusion, and molecules with high TPSA are often more polar, reducing their ability to permeate lipophilic biological membranes. Compounds with TPSA < 90 Å² (**5e–5p**) are more likely to cross the BBB, making it important in designing CNS-active drugs. The lipophilicity class, indicative of a molecule's solubility in lipophilic media, was assessed through iLOGP and SILICOS-IT. The iLOGP values fell within the acceptable range (−0.4 to +5.6), while SILICOS-IT values were highly favourable. Predicted intestinal absorption profiles indicated excellent absorption (>92%) for all identified leads. Water solubility, a crucial parameter affecting drug absorption and distribution, was evaluated through log*S* calculations. The calculated log*S* values (4.66–5.83) indicated moderate solubility, contributing to a good balance between permeability and solubility for oral drug administration. Predicted gastrointestinal (GI) absorption was high for all compounds. Permeability over human skin, an indicator of ADMET outcomes, ranged from −4.78 to −5.86, within acceptable limits. Metabolism predictions assessed interaction with cytochrome P450 enzymes (CYPs), revealing no significant inhibitory activity. Drug-likeness, an indicator of oral drug potential, was assessed using various filters. While some compounds exhibited moderate violations, others showed no violations and similar bioavailability scores (55%). Synthetic accessibility ranged from moderate to tough (0.363–0.82), and total renal clearance fell within normal values (0.739–0.984 ml min^{−1} kg^{−1}). Renal OCT2 substrate activity was observed for **5a**, **5b**, and **5d** but was negative for most compounds. Detailed analyses are provided in Table S15.†

Toxicity predictions were conducted for all analogues (**5a–p**) to assess their *in silico* toxicity profiles. The AMES test, utilized to determine the mutagenic potential of chemical compounds using bacteria, yielded favourable results for all compounds except **5d–5h** and **5m** which exhibited AMES toxicity. The maximum tolerated dose (human) ranged from −0.081 to −0.722 log mg per kg per day, representing a moderate level of dosage according to established protocols.

None of the compounds showed hERG I or II (human ether-a-go-go-related gene) inhibition, mitigating the risk of ventricular arrhythmia. Oral rat chronic toxicity (LD₅₀) values ranged from 2.301 to 3.111 mol kg^{−1}, while oral rat chronic toxicity (LOAEL) values ranged from 0.83 to 1.859 log mg per kg bw per day, indicating a favourable safety profile. Although all analogues were predicted to be hepatotoxic, none showed skin sensitization. The comprehensive toxicity results for these analogues are summarized in Table S16.†

This study aims to further explore the structure–activity relationship (SAR) by examining the influence of different R₁ and R₂ substitutions on the indolizine scaffold, which may play a critical role in the anti-TB activity against H37Rv, MDR, and XDR strains of MTB (Scheme 1).

3.8 Structure–activity relationship (SAR) of the indolizine scaffold

The significance of the indolizine core and its substituents in anti-tubercular potential has been evaluated through both earlier studies and the current research.^{23,24,27} This work focuses on the influence of various R₁ and R₂ substitutions on the indolizine scaffold (Fig. 9), which may play a critical role in anti-TB activity against H37Rv, as well as MDR and XDR strains of MTB. Findings from past literature and the present study suggest that the efficacy of indolizine derivatives in targeting both susceptible and drug-resistant MTB strains is highly dependent on the nature and position of these substituents, summarized as follows: the indolizine core is recognized for its potent pharmacological activity, particularly as an anti-tubercular agent. Incorporating a methoxy group into the indolizine scaffold significantly enhances its anti-TB potential. The presence of an ethyl ester at a specific position further ensures optimal activity against MTB. And current study suggested that an increase in anti-tubercular activity is observed with electron-withdrawing substituents at the R₁ position, while electron-donating groups also show considerable activity. However, halogen substitution at this position reduces the compound's efficacy




Fig. 9 Summary of the structure–activity relationship (SAR) of the indolizine scaffold.

(Table 3). Additionally, an ethyl carboxylate group at the R₂ position reduces *clogP* values (Table 1), improving the solubility of the compounds, which is crucial for their bioavailability and effectiveness.

4. Conclusions

The anti-tubercular activity of indolizine derivatives (**5a–p**) was evaluated against three MTB strains: H37Rv, rifampicin/isoniazid-resistant (MDR), and XDR. Compound **5e**, which has a nitro group on the benzoyl ring, exhibited the highest activity with a MIC of 4, 16, and 16 µg mL⁻¹ against H37Rv, MDR, and XDR strains of MTB. Compounds **5a**, **5f**, **5h**, and **5n** also showed good activity (MIC: 8 µg mL⁻¹). SAR analysis revealed that substitutions at the 2-position of the indolizine ring, such as hydrogen, methyl, ethyl, and ester groups, improved potency. Increased anti-tubercular activity was observed with electron-withdrawing substitutions at both the R₁ and R₂ positions. These findings suggest that the indolizine derivatives may inhibit different MTB molecular targets. Single crystal analysis revealed that the molecular assemblies of the indolizine derivatives are primarily governed by C–H⋯O hydrogen-bonded dimeric ring motifs, along with secondary interactions such as C–H⋯π and π⋯π interactions. The presence of hydrogen bonding is further confirmed by red spots and spikes in the 2D fingerprint plot of the Hirshfeld surface, indicating multiple interaction types. MEP analysis revealed sites for non-covalent interactions, including weak hydrogen bonds. Additionally, NCI and QTAIM analyses revealed the weak nature of intra- and intermolecular C–H⋯O hydrogen bonds in these derivatives in their solid state. In addition to these, a comprehensive ADMET analysis of all the compounds suggested a favourable toxicity profile and promising drug-like properties. These findings highlight the potential of these novel indolizine derivatives as promising candidates for further development in the fight against tuberculosis.

Data availability

CCDC 2380090–2380096 contain the supplementary crystallographic data for this paper. The datasets supporting this article have been uploaded as part of the ESI.†

Author contributions

Rahul D. Nagdeve: conceptualization, methodology, formal analysis, investigation, writing – original draft. Jyoti Swarup Thakur: software, validation, formal analysis, writing – review & editing. Sandeep Chandrashekarappa, Katharigatta N. Venugopala, Melendhran Pillay, Gourav Rakshit, and Pran Kishore Deb: methodology, resources, conceptualization. Pradip K. Mondal and Maurizio Polentarutti: single crystal X-ray data collection. Keshab M. Bairagi and Osama I. Alwassil: formal analysis, writing – review & editing. Susanta K. Nayak: supervision, funding acquisition, writing – review & editing.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

RDN thanks UGC-New Delhi, India, for providing financial assistance under UGC-JRF (JUNE18-136885) for the fellowship. RDN, JST, and SKN thank VNIT for providing research support. The authors are thankful for the single crystal data collection at the XRD1 beamline, Elettra Synchrotron, which was funded by a grant from the Italian Ministry of Foreign Affairs and International Cooperation and the Indian Department of Science & Technology. We also thank the Science and Engineering Research Board, India, (ECR/2016/001820) for the polarized optical microscope with hot stage equipment facility. KNV thanks the Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia (KFU242386), the Durban University of Technology, and the National Research Foundation (129330 and 129173), South Africa.

References

- H. Mohajan, *Tuberculosis is a Fatal Disease among Some Developing Countries of the World*, 2014, pp. 18–31.
- M. Zala, J. J. Vora and V. M. Khedkar, *ACS Omega*, 2023, **8**, 20262–20271.
- A. Ohkado and S. Kato, in *Pulmonary Tuberculosis and Its Prevention*, Springer, 2022, pp. 3–31.
- R. Panjabi, G. Comstock and J. Golub, *Int. J. Tuberc. Lung Dis.*, 2007, **11**, 828–837.
- F. Stephanie, M. Saragih and U. S. F. Tambunan, *Pharmaceutics*, 2021, **13**, 592.
- A. A. Adeniji, K. E. Knoll and D. T. Loots, *Appl. Microbiol. Biotechnol.*, 2020, **104**, 5633–5662.
- J. L. Khawbung, D. Nath and S. Chakraborty, *Comp. Immunol. Microbiol. Infect. Dis.*, 2021, **74**, 101574.
- P. Mundhe, S. Kidwai, S. M. Saini, H. R. Singh, R. Singh and S. Chandrashekarappa, *J. Mol. Struct.*, 2023, **1284**, 135359.
- K. N. Venugopala, S. Chandrashekarappa, P. K. Deb, C. Tratratt, M. Pillay, D. Chopra, N. A. Al-Shar'i, W. Hourani, L. A. Dahabiyeh and P. Borah, *J. Enzyme Inhib. Med. Chem.*, 2021, **36**, 1471–1486.
- N. J. Ryan and J. H. Lo, *Drugs*, 2014, **74**, 1041–1045.
- V. A. Dartois and E. J. Rubin, *Nat. Rev. Microbiol.*, 2022, **20**, 685–701.
- F. Andrade, D. Rafael, M. Videira, D. Ferreira, A. Sosnik and B. Sarmiento, *Adv. Drug Delivery Rev.*, 2013, **65**, 1816–1827.
- S. Parida, R. Axelsson-Robertson, M. Rao, N. Singh, I. Master, A. Lutckii, S. Keshavjee, J. Andersson, A. Zumla and M. Maeurer, *J. Intern. Med.*, 2015, **277**, 388–405.
- P. Tiwari, G. S. Mangubhai, S. Kidwai, R. Singh and S. Chandrashekarappa, *Chem. Biol. Drug Des.*, 2024, **103**, e14512.
- G. Stelitano, J. C. Sammartino and L. R. Chiarelli, *Molecules*, 2020, **25**, 1239.

- 16 V. Dartois and C. E. Barry, *Curr. Clin. Pharmacol.*, 2010, **5**, 96–114.
- 17 D. U. Ganihigama, S. Sureram, S. Sangher, P. Hongmanee, T. Aree, C. Mahidol, S. Ruchirawat and P. Kittakoop, *Eur. J. Med. Chem.*, 2015, **89**, 1–12.
- 18 C. Sandeep, B. Padmashali and R. S. Kulkarni, *Tetrahedron Lett.*, 2013, **54**, 6411–6414.
- 19 C. Sandeep, B. Padmashali, R. S. Kulkarni, S. Mallikarjuna, M. Siddesh, H. Nagesh and K. Thriveni, *Heterocycl. Lett.*, 2014, **4**, 371–376.
- 20 G. Sumanth, S. M. Saini, K. Lakshmikanth, G. S. Mangubhai, K. Shivaprasad and S. Chandrashekarappa, *J. Mol. Struct.*, 2023, **1286**, 135561.
- 21 K. Lakshmikanth, S. M. Saini, S. T. Dorai and S. Chandrashekarappa, *Tetrahedron*, 2023, 133516.
- 22 K. N. Venugopala, S. Chandrashekarappa, S. Bhandary, D. Chopra, M. A. Khedr, B. E. Aldhubiab, M. Attimarad and B. Odhav, *Curr. Org. Synth.*, 2018, **15**, 388–395.
- 23 K. N. Venugopala, S. Chandrashekarappa, M. Pillay, H. H. Abdallah, F. M. Mahomoodally, S. Bhandary, D. Chopra, M. Attimarad, B. E. Aldhubiab and A. B. Nair, *PLoS One*, 2019, **14**, e0217270.
- 24 M. A. Khedr, M. Pillay, S. Chandrashekarappa, D. Chopra, B. E. Aldhubiab, M. Attimarad, O. I. Alwassil, K. Mlisana, B. Odhav and K. N. Venugopala, *J. Biomol. Struct. Dyn.*, 2018, **36**, 2163–2178.
- 25 S. Chandrashekarappa, K. N. Venugopala, R. Venugopala and B. Padmashali, *J. Appl. Pharm. Sci.*, 2019, **9**, 124–128.
- 26 K. N. Venugopala, C. Tratratt, S. Chandrashekarappa, M. Attimarad, N. Sreeharsha, A. B. Nair, S. Pottathil, R. Venugopala, O. H. A. Al-Attaqchi and M. A. Morsy, *Indian J. Pharm. Educ. Res.*, 2019, **53**, 545–552.
- 27 K. N. Venugopala, C. Tratratt, M. Pillay, F. M. Mahomoodally, S. Bhandary, D. Chopra, M. A. Morsy, M. Haroun, B. E. Aldhubiab and M. Attimarad, *Antibiotics*, 2019, **8**, 247.
- 28 V. Uppar, S. Chandrashekarappa, A. I. Basarikatti, G. Banuprakash, M. K. Mohan, M. Chougala, K. K. Mudnakudu-Nagaraju, R. Ningegowda and B. Padmashali, *J. Appl. Pharm. Sci.*, 2020, **10**, 077–085.
- 29 C. Sandeep, B. Padmashali, R. S. Kulkarni, K. N. Venugopala, R. Venugopala and B. Odhav, *Asian J. Chem.*, 2016, **28**, 1043–1048.
- 30 C. Sandeep, P. Basavaraj and S. Rashmi, *J. Appl. Chem.*, 2013, **2**, 1049–1052.
- 31 V. Uppar, S. Chandrashekarappa, C. Shivamallu, S. P. Kollur, J. Ortega-Castro, J. Frau, N. Flores-Holguín, A. I. Basarikatti, M. Chougala and P. Sushma, *Molecules*, 2021, **26**, 2722.
- 32 K. N. Venugopala, O. H. Al-Attaqchi, C. Tratratt, S. K. Nayak, M. A. Morsy, B. E. Aldhubiab, M. Attimarad, A. B. Nair, N. Sreeharsha and R. Venugopala, *Biomolecules*, 2019, **9**, 661.
- 33 C. Sandeep, K. N. Venugopala, M. A. Khedr, B. Padmashali, R. S. Kulkarni, V. Rashmi and B. Odhav, *Indian J. Pharm. Educ. Res.*, 2017, **51**, 452–460.
- 34 S. Chandrashekarappa, K. N. Venugopala, C. Tratratt, F. M. Mahomoodally, B. E. Aldhubiab, M. Haroun, R. Venugopala, M. K. Mohan, R. S. Kulkarni and M. V. Attimarad, *New J. Chem.*, 2018, **42**, 4893–4901.
- 35 K. N. Venugopala, S. Chandrashekarappa, C. Tratratt, P. K. Deb, R. D. Nagdeve, S. K. Nayak, M. A. Morsy, P. Borah, F. M. Mahomoodally and R. P. Mailavaram, *Molecules*, 2021, **26**, 3550.
- 36 S. Chandrashekarappa, K. N. Venugopala, S. K. Nayak, R. M. Gleiser, D. A. García, H. M. Kumalo, R. S. Kulkarni, F. M. Mahomoodally, R. Venugopala and M. K. Mohan, *J. Mol. Struct.*, 2018, **1156**, 377–384.
- 37 C. Sandeep, K. N. Venugopala, R. M. Gleiser, A. Chetram, B. Padmashali, R. S. Kulkarni, R. Venugopala and B. Odhav, *Chem. Biol. Drug Des.*, 2016, **88**, 899–904.
- 38 O. I. Alwassil, S. Chandrashekarappa, S. K. Nayak and K. N. Venugopala, *PLoS One*, 2019, **14**, e0223413.
- 39 A. Lausi, M. Polentarutti, S. Onesti, J. Plaisier, E. Busetto, G. Bais, L. Barba, A. Cassetta, G. Campi and D. Lamba, *Eur. Phys. J. Plus*, 2015, **130**, 1–8.
- 40 W. Kabsch, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 125–132.
- 41 O. Dolomanov, *J. Appl. Crystallogr.*, 2009, **42**, 339–341.
- 42 G. M. Sheldrick, *Acta Crystallogr., Sect. A: Found. Adv.*, 2015, **71**, 3–8.
- 43 G. M. Sheldrick, *Acta Crystallogr., Sect. C: Struct. Chem.*, 2015, **71**, 3–8.
- 44 C. F. Macrae, I. J. Bruno, J. A. Chisholm, P. R. Edgington, P. McCabe, E. Pidcock, L. Rodriguez-Monge, R. Taylor, J. Streek and P. A. Wood, *J. Appl. Crystallogr.*, 2008, **41**, 466–470.
- 45 L. J. Farrugia, *J. Appl. Crystallogr.*, 1997, **30**, 565–565.
- 46 A. L. Spek, *Acta Crystallogr., Sect. C: Struct. Chem.*, 2015, **71**, 9–18.
- 47 J. J. McKinnon, D. Jayatilaka and M. A. Spackman, *Chem. Commun.*, 2007, 3814–3816.
- 48 M. A. Spackman, J. J. McKinnon and D. Jayatilaka, *CrystEngComm*, 2008, **10**, 377–388.
- 49 J. J. McKinnon, M. A. Spackman and A. S. Mitchell, *Acta Crystallogr., Sect. B: Struct. Sci.*, 2004, **60**, 627–668.
- 50 A. Parkin, G. Barr, W. Dong, C. J. Gilmore, D. Jayatilaka, J. J. McKinnon, M. A. Spackman and C. C. Wilson, *CrystEngComm*, 2007, **9**, 648–652.
- 51 M. A. Spackman and D. Jayatilaka, *CrystEngComm*, 2009, **11**, 19–32.
- 52 M. Turner, J. McKinnon, S. Wolff, D. Grimwood, P. Spackman, D. Jayatilaka and M. Spackman, *J. Appl. Crystallogr.*, 2021, **54**, 1006–1011.
- 53 M. J. Turner, S. Grabowsky, D. Jayatilaka and M. A. Spackman, *J. Phys. Chem. Lett.*, 2014, **5**, 4249–4255.
- 54 R. A. Gaussian09, Gaussian Inc., Wallingford CT, 2009, vol. 121, pp. 150–166.
- 55 Y. Erdogdu, D. Manimaran, M. Güllüoğlu, M. Amalanathan, I. Hubert Joe and S. Yurdakul, *Opt. Spectrosc.*, 2013, **114**, 525–536.
- 56 M. Frisch, G. Trucks, H. Schlegel, G. Scuseria, M. Robb, J. Cheeseman, G. Scalmani, V. Barone, B. Mennucci and G. Petersson, *Gaussian 09 Revision A*, 2009, vol. 1.

- 57 T. Lu and F. Chen, *Comput. Chem.*, 2012, **33**, 580–592.
- 58 W. Humphrey, A. Dalke and K. Schulten, *J. Mol. Graphics*, 1996, **14**, 33–38.
- 59 A. Martin, N. Morcillo, D. Lemus, E. Montoro, M. A. Telles, N. Simboli, M. Pontino, T. Porras, C. Leon, M. Velasco, L. Chacon, L. Barrera, V. Ritacco, F. Portaels and J. C. Palomino, *Int. J. Tuberc. Lung Dis.*, 2005, **9**, 901–906.
- 60 T. Mosmann, *J. Immunol. Methods*, 1983, **65**, 55–63.
- 61 A. Saeed, S. Ashraf, U. Flörke, Z. Y. D. Espinoza, M. F. Erben and H. Pérez, *J. Mol. Struct.*, 2016, **1111**, 76–83.
- 62 A. Saeed, Z. Ashraf, H. Nadeem, J. Simpson, H. Pérez and M. F. Erben, *J. Mol. Struct.*, 2019, **1195**, 796–806.
- 63 R. D. Nagdeve, J. S. Thakur, S. Chandrashekarappa, K. M. Bairagi, P. K. Deb, K. N. Venugopala, P. K. Mondal, M. Polentarutti, O. I. Alwassil and V. Mohanlall, *J. Mol. Struct.*, 2024, **1308**, 138080.
- 64 A. J. Edwards, C. F. Mackenzie, P. R. Spackman, D. Jayatilaka and M. A. Spackman, *Faraday Discuss.*, 2017, **203**, 93–112.
- 65 C. F. Mackenzie, P. R. Spackman, D. Jayatilaka and M. A. Spackman, *IUCrJ*, 2017, **4**, 575–587.
- 66 R. J. Xavier and E. Gobinath, *Spectrochim. Acta, Part A*, 2012, **86**, 242–251.
- 67 H. Gökce and S. Bahçeli, *Spectrochim. Acta, Part A*, 2013, **114**, 61–73.
- 68 T. Koopmans, *Physica*, 1934, **1**, 104–113.
- 69 A. Bendjeddou, T. Abbaz, S. Maache, A. Gouasmia and D. Villemin, *Int. J. Pharm. Sci. Rev. Res.*, 2016, **39**, 136–143.
- 70 R. Bader, *Atoms in molecules “A quantum theory”*, Clarendon, Oxford, UK, 1990.
- 71 U. Koch and P. L. Popelier, *J. Phys. Chem.*, 1995, **99**, 9747–9754.
- 72 R. Parthasarathi, V. Subramanian and N. Sathyamurthy, *J. Phys. Chem. A*, 2005, **109**, 843–850.